Related Experiment Video
Updated: Aug 17, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
Published on: February 9, 2011
MRSA--what is it, and how do we deal with the problem?
1Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, NJ 07065, USA. john_barrett2@merck.com
Abstract:
Methicillin-resistant Staphylococcus aureus (MRSA) has become a serious nosocomial pathogen, and more recent reports in the scientific literature underscore the potential issues with emerging community-MRSA. MRSA is reported to be involved in > 50% of hospital S. aureus infections, more in the intensive care unit (ICU) than the non-ICU, and increases in multi-drug resistant MRSA and increasingly virulent MRSA have been reported. Together with its broad-based beta-lactam resistance, MRSA often possesses a multi-drug resistance genotype, including cephalosporins, aminoglycosides, fluoroquinolones, and macrolide resistances. MRSA has now emerged as the predominant nosocomial Gram-positive pathogen, and it has a high rate of morbidity and mortality. Action must be taken to contain and eradicate MRSA through a combination of infection control, the development of novel anti-MRSA agents, development of vaccines and other non-traditional approaches of intervention.
Insights
Methicillin-resistant Staphylococcus aureus (MRSA) is a growing threat in hospitals, causing over half of infections. Urgent action is needed to combat this multidrug-resistant pathogen through infection control and new treatments.
Area of Science:
- Infectious Diseases
- Microbiology
- Public Health
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a significant hospital-acquired pathogen.
- MRSA accounts for over 50% of Staphylococcus aureus hospital infections, with higher rates in ICUs.
- Increasing prevalence of multidrug-resistant and hypervirulent MRSA strains is a major concern.
Purpose of the Study:
- To highlight the escalating threat of MRSA in healthcare settings.
- To underscore the broad-spectrum resistance and high morbidity/mortality associated with MRSA.
- To emphasize the urgent need for comprehensive strategies against MRSA.
Main Methods:
- Literature review of current MRSA prevalence and resistance patterns.
- Analysis of MRSA's role in nosocomial infections.
- Assessment of MRSA's resistance mechanisms, including beta-lactams, cephalosporins, aminoglycosides, fluoroquinolones, and macrolides.
Main Results:
- MRSA is the predominant Gram-positive nosocomial pathogen.
- MRSA infections are associated with high rates of morbidity and mortality.
- MRSA exhibits resistance to multiple antibiotic classes.
Conclusions:
- Comprehensive control measures are essential to contain and eradicate MRSA.
- Development of novel anti-MRSA agents is crucial.
- Vaccines and non-traditional interventions are needed to combat MRSA effectively.
More Related Videos
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Microbial Bioremediation of Hydrocarbons
Staphylococcal Skin Infections
Microbial Corrosion
Benzene to 1,4-Cyclohexadiene: Birch Reduction Mechanism

